Consultants

Michael Kurman, M.D., Medical Oncology Consultant
Minesh Mehta, M.D., FASTRO, Radiation Oncology Consultant
Joanne Mortimer, M.D., FACP., Medical Oncology Consultant
George Sgouros, Ph.D., Radiation Oncology Consultant
Richard Wahl, M.D., Radiation Oncology Consultant

Michael Kurman, M.D., Medical Oncology Consultant
Michael Kurman, M.D. is an independent consultant to the pharmaceutical, biotechnology and health care industries specializing in oncology and oncology drug development, with 24 years of experience. He received his B.S. in Biology from Syracuse University graduating summa cum laude and received his M.D. degree from Cornell University Medical College. Dr. Kurman started his career in the practice of oncology, during which he was an investigator on several oncology clinical trials. Since joining industry, he has held positions of progressively more responsibility in Janssen, Cytogen and US Bioscience, and was involved in the successful development or launch of four oncology products. Before starting his consultancy, Dr. Kurman was Vice President of Clinical Operations for Quintiles? Oncology Division. His primary interests are in early/late phase oncology clinical trial design and drug development, and in strategic portfolio management. In addition, he serves on the Scientific Advisory Boards of several companies and is on the Board of Directors of Avalon Pharmaceuticals. Dr. Kurman is board certified in Internal Medicine and Oncology, and did his oncology training at Mt. Sinai Hospital in New York.
Top

Minesh Mehta, M.D., FASTRO, Radiation Oncology Consultant
Minesh P. Mehta, M.D., is professor of Radiation Oncology at the Northwestern University Feinberg School of Medicine. Board-certified in Radiation Oncology, Dr. Mehta specializes in the management of patients with benign and malignant tumors, vascular malformations, and other brain conditions such as trigeminal neuralgia, as well as in the area of thoracic tumors. He maintains an active interest in radiation-drug interactions, amelioration of radiation toxicities, incorporation of advanced radiation and imaging technologies, and is keenly interested in expanding the frontiers of personalized care in radiotherapy.
Top

Joanne Mortimer, M.D., FACP., Medical Oncology Consultant
Dr. Mortimer is the Vice Chair for Medical Oncology at the City of Hope. She is also Associate Director for Affiliate Programs and the Administrative Director for Phase I Programs. Dr. Mortimer has participated in clinical trials in Breast Cancer research for over 25 years. Her research has focused on assessing the effects of systemic therapies on cancer and normal tissues. Previously, Dr. Mortimer was the Deputy Director of Medical Oncology at Moores Cancer Center at the University of California, San Diego, Medical Director of the Sentara Cancer Institute, Head of Hematology and Medical Oncology and Professor of Internal Medicine at the Eastern Virginia Medical School, Director of Clinical Oncology and Professor of Medicine at the Washington University School of Medicine in St. Louis, Associate of Clinical Research at the Fred Hutchinson Cancer Center in Seattle, and Assistant Professor at the University of Washington’s School of Medicine. Dr. Mortimer is currently a consulting member of the Oncologic Drug Advisory Committee of the U.S. Food and Drug Administration.
Top

George Sgouros, Ph.D., Radiation Oncology Consultant
Dr. George Sgouros is Professor of Radiology and Radiological Sciences, Director of Radiopharmaceutical Dosimetry Section, Division of Nuclear Medicine in the Russel H. Morgan Dept of Radiology and Radiological Sciences at The Johns Hopkins University, School of Medicine. He received his Bachelor’s degree from Columbia University, School of Engineering and Applied Science and his Ph.D. from Cornell University, Graduate School of Medical Sciences. Dr. Sgouros has had over fifteen years experience in modeling and dosimetry of internally administered radionuclides, with a particular emphasis on alpha-particle emitters and on using mathematical models to assess novel targeted therapy strategies. He is co-editor of a book on Monte Carlo calculations in Nuclear Medicine and author on numerous chapters, peer-reviewed publications and conference proceedings in targeted radionuclide therapy and radionuclide dosimetry. He is Chairman of the Medical Internal Radionuclide Dose (MIRD) Committee as well as steering committee member of the American Association of Physicists in Medicine, Task Group on Internal Emitter Dosimetry. He has also served as chairman of the Dosimetry & Radiobiology Panel at a Department of Energy Workshop on alpha-emitters in medical therapy and on the Oncological Sciences IRG Study Section Boundaries Team at the NIH Center for Scientific Review.
Top

Richard Wahl, M.D., Radiation Oncology Consultant
Dr. Richard Wahl was born in Waverly, Iowa and graduated as valedictorian from Wartburg College in Iowa in 1974 with a summa cum laude degree in Chemistry. He received his M.D. from Washington University School of Medicine in 1978, and was elected to Alpha Omega Alpha. After internship at the University of California San Diego, he returned to St. Louis for Diagnostic Radiology and Nuclear Medicine training at Washington University, where he also served as a research fellow in the Department of Immunology. In 1983, Dr. Wahl joined the faculty of the University of Michigan, and became Professor of Internal Medicine and Radiology in 1990. He co-directed and directed the General Nuclear Imaging Section and was Director of the Cancer Radiopharmaceutical Program within the University of Michigan Cancer Center.In 2000, Dr. Wahl joined the Johns Hopkins University faculty as Director of the Division on Nuclear Medicine; Director of the Positron Emission Tomography (PET) Center; and Vice Chair for Technology and New Business Development within the Russell H. Morgan Department of Radiology and Radiological Sciences. Dr. Wahl’s primary research has included the diagnosis and treatment of cancer through the use of specifically targeted radiopharmaceuticals. Over the past 20 years, Dr. Wahl has been involved in the development of “smart radiopharmaceuticals”-targeting tumors for therapy and spare healthy tissue. He is a leading expert in PET, and was cited by the Academy of Molecular Imaging as the first person in the United States to apply PET technology to accurately diagnose a broad array of human cancers. Dr. Wahl was one of the first to develop radio-immunotherapy for the treatment of non-Hodgkin?s lymphoma. Dr. Wahl also pioneered computer methods that joined PET and CT technologies to form “fusion” images of cancer, and has been involved in the early stage evaluation of PET CT fusion technologyan increasingly routine procedure at Johns Hopkins. Dr. Wahl is the principal editor of a best selling imaging textbook, Principles and Practice of Positron Emission Tomography, and co-author of the II Atlas of Clinical PET Imaging”. He currently serves on the editorial boards of The Journal of Nuclear Medicine; MolecularImaging and Biology; and Bioconjugates. He has authored over 220 peer-reviewed manuscripts, has served on several NIH study sections and currently serves on the Medicare Technology Advisory Committee. He has been chairman of American Board of Nuclear Medicine. Dr. Wahl has received multiple awards including the Berson and Yalow Award; Tetalman Award of the Society of Nuclear Medicine; The Hounsfield Award of the Society of Body CT; Academy of Molecular Imaging Distinguished Scientist Award and has been honored as the New Horizons Lecturer for the Radiological Society of North America. Dr. Wahl is extremely honored to be the first recipient of the Henry N. Wagner, Jr., M.D. Professorship in Nuclear Medicine.
Top